BC Week In Review | Oct 11, 2010
Company News

Acea Biosciences, Vivo Biosciences deal

Acea and Vivo partnered to develop label-free, real-time cell-based assays for Acea's xCELLigence system. The new assays will use Vivo's HuBiogel technology, a human-derived biomatrix system which allows for growth, proliferation and differentiation of primary,...
BC Week In Review | Jul 20, 2009
Company News

Pegasus Biologics, Synovis Life Technologies Inc. deal

Medical device company Synovis will acquire substantially all of the assets of tissue repair company Pegasus for $12.1 million in cash. The assets include Pegasus' marketed products OrthAdapt Bioimplant, a type I collagen scaffold for...
BC Week In Review | Nov 22, 2004
Clinical News

BioMatrix cardiovascular data

In the double-blind, German and Brazilian STEALTH trial in 120 patients, angiographic analysis at 6 months showed the BioMatrix group had a lower restenosis rate compared to the bare metal stent group (3.9% vs. 7.7%,...
BC Week In Review | Nov 8, 2004
Company News

Genzyme, Wyeth sales and marketing update

GENZ acquired from WYE sales and marketing rights for osteoarthritis drug Synvisc hylan G-F 20 in the U.S. and five European countries (Germany, Poland, Greece, Portugal and the Czech Republic). In exchange, WYE will receive...
BC Extra | Nov 4, 2004
Company News

Genzyme to buy back Synvisc rights

GENZ will acquire from Wyeth (WYE) the marketing rights to osteoarthritis drug Synvisc hylan G-F 20 in the U.S. and five European countries. GENZ already markets the drug in certain countries. In 1997, WYE gained...
BC Week In Review | Jun 9, 2003
Company News

Genzyme General Corp., Genzyme Biosurgery Inc. biopharmaceuticals news

GZBX shareholders Rory Riggs and John Lewis filed suit in the U.S. District Court for the Southern District of New York seeking to block the sale of GZBX stock to GENZ. The shareholders said the...
BioCentury | Jun 9, 2003
Finance

Ebb & Flow

There's an old Wall Street adage that stock tips given around the shoe shine box or barber poll should be taken as red-hot sell indicators. Perhaps the same should apply to biotech, given that the...
BC Extra | Jun 3, 2003
Top Story

GZBX consolidation opposed

Genzyme Biosurgery (GZBX) shareholders Rory Riggs and John Lewis filed suit in the U.S. District Court for the Southern District of New York seeking to block the sale of GZBX stock to Genzyme (GENZ). The...
BioCentury | May 12, 2003
Finance

Family values

Genzyme Corp. is well known for using creative financing structures to the best advantage of the mother company. Thus it should have come as no surprise that Genzyme General is taking advantage of the depressed...
BC Week In Review | Dec 4, 2000
Company News

Biomatrix, Farmila Farmaceutici Milano S.p.A. sales and marketing update

Farmila subsidiary Euroderm s.r.l. launched in Italy, France and Spain four BXM skin care products based on BXM's Hylasome cross-linked hyaluronan technology. Euroderm, which has an exclusive license in the territory for two years, markets...
Items per page:
1 - 10 of 93